Stockscreener 앱 받기
35.38
0.08%
0.0295
전일 마감가:
$35.35
열려 있는:
$35.52
하루 거래량:
1.98M
Relative Volume:
0.27
시가총액:
$41.19B
수익:
$17.53B
순이익/손실:
$1.58B
주가수익비율:
26.29
EPS:
1.3457
순현금흐름:
$444.18M
1주 성능:
+11.89%
1개월 성능:
+17.62%
6개월 성능:
+43.82%
1년 성능:
+115.86%
1일 변동 폭
$35.08
$35.76
1주일 범위
$33.92
$36.02
52주 변동 폭
$14.99
$37.34
테바 ADR Stock (TEVA) Company Profile
명칭
Teva Pharmaceutical Industries Ltd Adr
전화
972 (3) 914-8213
주소
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
Compare TEVA vs TAK, ZTS, HLN, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.38 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
TAK
Takeda Pharmaceutical Co Adr
|
16.54 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.77 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.15 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
578.47 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
테바 ADR Stock (TEVA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-12-05 | 개시 | Scotiabank | Sector Outperform |
| 2025-06-06 | 개시 | Goldman | Buy |
| 2025-05-28 | 개시 | Truist | Buy |
| 2025-05-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-07-10 | 업그레이드 | Argus | Hold → Buy |
| 2024-03-08 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-02-12 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-01-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-01-03 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2023-12-18 | 개시 | HSBC Securities | Buy |
| 2023-11-27 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-06 | 업그레이드 | UBS | Sell → Neutral |
| 2023-05-25 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-05-18 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-01-19 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-11-14 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-11-04 | 다운그레이드 | UBS | Neutral → Sell |
| 2022-10-21 | 재개 | Jefferies | Buy |
| 2022-08-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-06-14 | 재개 | UBS | Neutral |
| 2022-05-17 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-05-04 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
| 2022-04-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2022-03-25 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2022-01-27 | 다운그레이드 | Argus | Buy → Hold |
| 2021-10-28 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-05-04 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2020-11-25 | 개시 | Oppenheimer | Perform |
| 2020-08-06 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2020-07-27 | 재개 | Goldman | Neutral |
| 2020-06-01 | 업그레이드 | SunTrust | Hold → Buy |
| 2020-04-24 | 재개 | Citigroup | Neutral |
| 2020-04-06 | 업그레이드 | UBS | Neutral → Buy |
| 2020-02-24 | 다운그레이드 | Edward Jones | Hold → Sell |
| 2019-11-12 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2019-10-17 | 업그레이드 | Gabelli & Co | Hold → Buy |
| 2019-08-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-07-19 | 개시 | Wolfe Research | Peer Perform |
| 2019-07-15 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2019-07-10 | 재개 | Credit Suisse | Neutral |
| 2019-07-05 | 업그레이드 | Argus | Hold → Buy |
| 2019-06-11 | 개시 | Barclays | Underweight |
| 2019-06-03 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-05-30 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2019-05-28 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-03-20 | 개시 | SunTrust | Hold |
| 2019-03-07 | 재개 | UBS | Buy |
모두보기
테바 ADR 주식(TEVA)의 최신 뉴스
Reddit Upgraded, Spotify Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Why Teva (TEVA) Is Up 14.1% After Strong Q1 Profitability And Neuroscience Pivot News - Sahm
Teva Pharmaceutical (TEVA) Q1 EPS Of US$0.32 Tests Bullish Profitability Narrative - Sahm
Teva Signals Confidence With $700 Million Pipeline Push, Buyback Plan - Sahm
Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets - Sahm
Teva’s Home Ground Schizophrenia Push And What It Could Mean For Investors - Sahm
Teva Signals Confidence With $700 Million Pipeline Push, Buyback Plan - Benzinga
Teva Enjoys Strong Start to 2026 Thanks to Strong Momentum in Branded Portfolio - Morningstar
Earnings call transcript: Teva beats Q1 2026 forecasts, stock surges 7.5% - Investing.com
Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy - Sahm
Intel Upgraded, Toyota Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Dermatomycoses Market Report 2025-2035, Profiles of Prominent Players - GlobeNewswire Inc.
Is It Too Late To Reassess Teva (TEVA) After Its 118.5% One-Year Surge? - Sahm
Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After The Home Ground Schizophrenia Platform Launch - Sahm
Teva- Pharmaceutical Industries Ltd.ADR (TEVA) News, Articles, Events & Latest Updates - Stocktwits
Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners - Sahm
Teva Pharmaceutical (ADR) stock (US88162G1031): Why generic drug execution is suddenly worth a close - AD HOC NEWS
Does Biosimilar Wins in Osteoporosis and Allergy Care Change The Bull Case For Teva (TEVA)? - Sahm
A Look At Teva Pharmaceutical Industries (TEVA) Valuation After Recent Biosimilar Regulatory Milestones - Sahm
Target Upgraded, Robinhood Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
How Investors Are Reacting To Teva (TEVA) Advancing Its Biosimilar Pipeline With New FDA and EMA Milestones - Sahm
Assessing Teva Pharmaceutical Industries (TEVA) Valuation After New Biosimilar Approvals And Pipeline Progress - Sahm
Missile Strike Tests Teva Supply Resilience And Biosimilar Growth Plans - Sahm
Price to sales ratio of Teva Pharmaceutical Industries Limited Sponsored ADR – BSESOF:TEV - TradingView
Teva’s New Biosimilars Test Growth Plan And Earnings Reshaping Potential - Sahm
ETFs Investing in Teva Pharmaceutical Industries Limited Sponsored ADR Stocks - TradingView
How Investors May Respond To Teva (TEVA) Advancing TEV ‘325 In Biologics For Inflammatory Diseases - Sahm
Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Recent Share Price Weakness - Sahm
TEVA Stock Price, Quote & Chart | TEVA PHARMACEUTICAL-SP ADR (NYSE:TEVA) - ChartMill
Teva Pharmaceutical Industries Limited Sponsored ADR Trade Ideas — LS:883035 - TradingView
Teva Releases Q1 2026 Aide Memoire - Sahm
Will Teva’s (TEVA) Olanzapine LAI Milestone and Legal Win Change Its Innovation-Led Narrative? - Sahm
Tesla Upgraded, Super Micro Computer Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
How Teva’s Blackstone-Backed ‘Pivot to Growth’ Strategy Could Reshape Teva Pharmaceutical Industries (TEVA) Investors - Sahm
Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Pivot To Growth Update At Leerink Conference - Sahm
Teva Blackstone Duvakitug Deal Tests Growth Story And Concentration Risk - Sahm
Teva Drug Updates Support Branded Growth Story And Valuation Upside Potential - Sahm
What's Driving the Market Sentiment Around Teva Pharmaceutical Industries Ltd? - Sahm
Duvakitug IBD Data and TEV-749 Filing Might Change The Case For Investing In Teva (TEVA) - Sahm
Teva to Present at the Upcoming Investor Conferences in March - Sahm
J&J Stock Up 38% in 6 Months: Should You Buy, Sell or Hold? - Finviz
Where is Teva Pharmaceutical Industries Limited (TEVA) Headed? - Finviz
Corcept's Q4 Earnings and Revenues Fall Short of Estimates - Finviz
FDA Accepts Teva's New Long-Acting Schizophrenia Treatment Application - Sahm
Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Its Strong Recent Share Price Momentum - Sahm
테바 ADR (TEVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.94%
0.59%
자본화:
|
볼륨(24시간):